董事Luke Evnin报告在三天内出售了 Werewolf Therapeutics, Inc. (NASDAQ:HOWL) 的普通股，交易总额约为61,787美元。这些交易发生在2026年1月13日至1月15日期间，价格范围在0.55美元至0.57美元之间。根据 InvestingPro 数据，这家市值仅为2718万美元的微型生物技术公司在过去一年中股价下跌了超过60%。
The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...
董事Evnin Luke报告在2026年1月8日至2026年1月12日期间出售了 Werewolf Therapeutics Inc (NASDAQ:HOWL) 的股票。这些交易总计53,533美元，执行价格在0.57美元至0.63美元之间。
2 天on MSN
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging ...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago. These ...
HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈